Congressional spending plan: What’s in it for healthcare, and what isn’t
Chief Healthcare Executive December 21, 2024
GLP-1 Drugs Tied to Reduced Risk of Dangerous Blood Clots
MedPage Today December 8, 2024
— 20% lower risk of VTE observed in large retrospective study of diabetes patients
SAN DIEGO — Type 2 diabetes patients may have a lower risk of venous thromboembolism (VTE) when treated with a GLP-1 receptor agonist, regardless of their obesity status, a database study involving more than half a million patients found.
Propensity-score matched analysis showed that VTE rates at 1 year were 20% lower for patients starting on a GLP-1 drug rather than a DPP-4 inhibitor (6.5 vs 7.9 per 1,000 patient-years, HR 0.80, 95% CI 0.75-0.85, P<0.001), reported Rushad Patell, MD, of Harvard Medical School in Boston.
Subgroup analysis showed a lower risk associated with GLP-1 use both for pulmonary embolism (3.1 vs 3.9 per 1,000 patient-years,...
Today's Sponsors
Today's Sponsor